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Thin filament myopathies are among the most common non-
dystrophic congenital muscular disorders and are caused by 
mutations in genes encoding proteins that are associated with 
the skeletal muscle thin filament. Mechanisms underlying muscle 
weakness are poorly understood, but might involve the length of 
the thin filament, an important determinant of force generation. 
We investigated the sarcomere length-dependence of force, a 
functional assay that provides insights into the contractile strength 
of muscle fibers as well as the length of the thin filaments, in 
muscle fibers from 51 patients with thin filament myopathy caused 
by mutations in NEB, ACTA1, TPM2, TPM3, TNNT1, KBTBD13, 
KLHL40, and  KLHL41 .
Lower force generation was observed in muscle fibers from 
patients of all genotypes. In a subset of patients who harbor 
mutations in NEB  and ACTA1 ,  the lower force was associated with 
downward shifted force–sarcomere length relations, indicative of 
shorter thin filaments. Confocal microscopy confirmed shorter 
thin filaments in muscle fibers of these patients. A conditional 
NEB  knockout mouse model, which recapitulates thin filament 
myopathy, revealed a compensatory mechanism; the lower force 
generation that was associated with shorter thin filaments was 
compensated for by increasing the number of sarcomeres in series. 
This allowed muscle fibers to operate at a shorter sarcomere length 
and maintain optimal thin–thick filament overlap.
These findings might provide a novel direction for the development 
of therapeutic strategies for thin filament myopathy patients with 






Nemaline myopathy and congenital fiber type disproportion are 
among the most common non-dystrophic congenital muscular 
disorders1. Genes that are implicated in these myopathies encode 
proteins that are either components of the skeletal muscle thin 
filament, including nebulin (NEB), skeletal muscle alpha-actin1 
(ACTA1), beta-tropomyosin 2 (TPM2), alpha-tropomyosin 3 
(TPM3), troponin T type 1 (TNNT1), cofilin-2 (CFL2), and 
leiomodin-3 (LMOD3), or are thought to contribute to stability 
or turnover of thin filament proteins, such as kelch repeat and 
BTB (POZ) domain containing 13 (KBTBD13), and kelch like 
family members 40 (KLHL40) and 41 (KLHL41)2-6.  Hence, muscle 
diseases caused by mutations in these genes are here referred 
to as thin filament myopathies. For a schematic of the thin 
filament and its associated proteins, see Figure 1. Patients with 
thin filament myopathy suffer from muscle weakness, but the 
underlying mechanisms are poorly understood. The thin filament 
is a major constituent of the sarcomere, the smallest contractile 
unit in muscle, and is essential for force generation; its length 
determines the overlap between the thin and thick filament, and 
thereby the number of force-generating interactions that can be 
formed between actin and myosin. In healthy human muscle, the 
length of the thick filament is 1.6μm and that of the thin filament 
is regulated at 1.1 to 1.3μm7. Accordingly, force depends on 
sarcomere length, with increasing force as the overlap between thick 
and thin filaments increases (up to a sarcomere length of ∼2.6μm; 
ie, the ascending limb of the force–sarcomere length relation), 
and decreasing force at longer sarcomere lengths as the overlap 
between thick and thin filaments decreases (ie, the descending 
limb; Figure 2A8, 9).  Hence, appropriate length of the thin filament 
is important for muscle fiber strength; a shorter length causes 
lower force generation by shifting the descending limb of the 




Figure 1. Schematic of the skeletal muscle thin filament
The thin filament is an essential structure in the sarcomere, the smallest 
contractile unit in skeletal muscle. The actin-based backbone of the thin 
filament is decorated with proteins that are involved in the regulation of thin 
filament length and in muscle activation. Tropomyosin and the troponin complex 
decorate the thin filament along its entire length and are important players in 
thin filament activation13. Actin, nebulin, and leiomodin-3 are involved in both 
specifying the length of the thin filament and thin filament activation6, 13, 14. 
Both cofilin-2 and the kelch proteins—KBTBD13, KLHL40, and KLHL41—are 
associated with thin filament proteins: cofilin-2 by regulating actin dynamics15, 
KLHL40 and KLHL41 by interacting with nebulin, and KLHL40 by stabilizing 
leiomodin-3. The role of KBTBD13 has not yet been elucidated, but as it is 
required for the formation of a functional cullin-3 ubiquitin ligase complex, and 
as mutations in KBTBD13 result in thin filament myopathy, it is hypothesized 
to be involved in stabilizing thin filament proteins16 
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Whether mutations in genes implicated in thin filament myopathy 
contributes to force loss by affecting thin filament length is 
unclear. Mouse models with mutations in Neb  exhibit a shorter 
thin filament length associated with lower force generation that 
becomes more prominent as sarcomere length increases10-12. 
Preliminary studies on a small number of human biopsies were 
largely in agreement with this observation17, 18.  Whether these 
findings translate to a large group of patients, and whether 
shorter thin filament length is a general mechanism underlying 
force loss in thin filament myopathies with a variety of different 
gene defects, is unknown.
Therefore, we studied muscle fibers from 51 patients with thin 
filament myopathy caused by mutations in NEB, ACTA1, TPM2, 
TPM3, TNNT1, KBTBD13, KLHL40,  and KLHL41 .  In these fibers, 
we determined the sarcomere length-dependence of force, a 
functional assay that provides insight into the contractile strength 
of muscle fibers as well as the length of the thin filaments. In a 
novel, conditional Neb  knockout mouse model that recapitulates 
thin filament myopathy - including shorter thin filament length - 
we studied whether muscle possesses mechanisms that compensate 
for shorter thin filament length, and we specifically focused on 
the addition of sarcomeres in series. 
MATERIAL & METHODS
Muscle biopsies
Ethical approval for the use of muscle specimens remaining from 
diagnostic procedures or obtained during clinically indicated 
surgical procedures was obtained from the human research 
ethics committees of Boston Children’s Hospital institutional 
review board (03-08-128R; NEB-1–NEB-3; ACTA1-1–ACTA1-4; 
KLHL40-1; KLHL41-1), Children’s Hospital at Westmead (10/
CHW/45; ACTA1-5–ACTA1-13; TPM3-1–TPM3-10; TPM2-1–




Neurogenetic Disorders of Childhood Section, National Institutes 
of Health, Bethesda, Maryland (TPM3-11–12), Pitié-Salpêtrière 
Hospital Group in Paris (DC-2012-1693; NEB-4–NEB-7, NEB-9, 
ACTA1-14), Radboud University Medical Center in Nijmegen 
(KBTBD13-1–KBTBD13-10), Children’s Hospital of the University 
of Helsinki (6/E7/2005; NEB-8), and Hadassah Medical Center 
in Jerusalem (0421-14-HMO; TNNT1-1). Supplementary Table 1 
shows the clinical and genetic data of the subjects who were 
biopsied. From all participants, written informed consent was 
obtained for genetic testing and biobanking of muscle. CTRL 1–8 
are control subjects with no medical history. All biopsies were 
stored frozen and unfixed at −80°C until use.
Permeabilized muscle fiber mechanics
Small strips dissected from the muscle biopsies were permeabilized 
overnight as described previously17.  This procedure renders the 
membranous structures in the muscle fibers permeable, which 
enables activation of the myofilaments with exogenous calcium. 
Preparations were washed thoroughly with relaxing solution and 
stored in 50% glycerol/relaxing solution at −20°C. Small muscle 
bundles (cross-sectional area = ∼0.07mm2, in case of atrophic 
fibers in patients) and single muscle fibers (control subjects and 
mildly affected patients) were dissected from the permeabilized 
strips, and were mounted using aluminum T-clips between a length 
motor (ASI 403A; Aurora Scientific, Aurora, Ontario, Canada) 
and a force transducer element (ASI 315C-I, Aurora Scientific) 
in a single fiber apparatus (ASI 802D, Aurora Scientific) that was 
mounted on the stage of an inverted microscope (Axio Observer A1; 
Carl Zeiss, Oberkochen, Germany). Sarcomere length was set 
using a high speed VSL camera and ASI 900B software (Aurora 
Scientific). Mechanical experiments were performed at incremental 
sarcomere lengths: 2.0, 2.2, 2.5, 2.8, 3.2, and 3.5μm. Fiber width 
and diameter were measured at 3 points along the fiber, and the 
cross-sectional area was determined assuming an elliptical cross 
section. Three different types of bathing solutions were used during 
the experimental protocols: a relaxing solution (100mM N,N-Bis-
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(2-hydroxyethyl)-2-aminoethanesulfonic acid [BES], 6.97mM 
ethyleneglycoltetraacetic acid [EGTA], 6.48mM MgCl2, 5.89mM 
Na2–adenosine triphosphate [ATP], 40.76mM K-propionate, 
14.5mM creatine phosphate), a preactivating solution with low 
EGTA concentration (100mM BES, 0.1mM EGTA, 6.42mM MgCl2, 
5.87mM Na2-ATP, 41.14mM K-propionate, 14.5mM creatine 
phosphate, 6.9mM hexamethylenediaminetetraacetic acid), and 
an activating solution (100mM BES, 7.0mM Ca-EGTA, 6.28mM 
MgCl2, 5.97mM Na2-ATP, 40.64mM K-propionate, 14.5mM 
creatine phosphate). The temperature of the bathing solutions was 
kept constant at 20°C using a TEC controller (ASI 825A, Aurora 
Scientific). To prevent rundown of force during the protocol, 
muscle preparations were mounted in a relaxation solution at 1°C. 
Subsequently, the muscle preparations were preactivated by 
switching to an activation solution at 1°C. In that way, fibers 
were loaded with calcium, but no force was generated. By rapid 
switching to an activation solution at 20°C, the fibers were 
activated and force was generated. This procedure minimizes the 
duration of activation and force rundown. After the force plateau 
was reached, relaxation was induced by switching back to the bath 
with relaxation solution19, 20. 
Myosin heavy chain isoform analysis
A specialized sodium dodecyl sulfate (SDS)–polyacrylamide gel 
electrophoresis was used to determine the myosin heavy chain 
isoform composition of the muscle fiber preparations that we 
used in our contractility experiments17.  In brief, muscles fibers 
were denatured by boiling for 2 minutes in SDS sample buffer 
and electrophoresis was performed for 24 hours at 15°C and a 
constant voltage of 275Vt using a 4% stacking gel (pH=6.7), and 
a 7% separating gel (pH=8.7) with 30% glycerol (vol/vol). Finally, 
the gels were silver-stained, scanned, and analyzed with One-





To assess nebulin protein levels, muscle samples from CTRL (n=5) 
and NEB  (n=7) were homogenized and analyzed on 1% agarose 
electrophoresis gels, as previously described21. To prevent 
protein degradation, all buffers contained protease inhibitors 
(phenylmethylsulfonyl fluoride, 0.5mM; leupeptin, 0.04mM; E64, 
0.01mM). Gels were scanned and analyzed with One-Dscan EX 
software. The integrated optical density of nebulin and myosin 
heavy chain was determined. For Western blot analysis, 1- or 2-color 
infrared Western blots were scanned (Odyssey Infrared Imaging 
System; LI-COR Biosciences, Lincoln, NE) and the images were 
analyzed with One-Dscan EX software.
Confocal microscopy
Small muscle strips were dissected and permeabilized as described 
above in the Permeabilized Muscle Fiber Mechanics section. 
Immunolabeling and confocal scanning laser microscopy were 
performed as described previously12.  In brief, muscle bundles 
were stretched and fixed on a glass slide, and incubated with 
the following antibodies: Alexa Fluor 488 conjugated phalloidin 
(A12379; Invitrogen, Carlsbad, CA) to stain the thin filament; 
and a cocktail of primary antibodies against slow skeletal myosin 
heavy chain (ab11083; Abcam, Cambridge, MA) and fast skeletal 
myosin heavy chain (ab51263, Abcam) followed by Alexa Fluor 594 
(goat antimouse, Invitrogen) as secondary antibody to stain the 
thick filament. Images were captured using a Leica (Wetzlar, 
Germany) DM IRE2 Confocal Laser Scanning Microscope. From 
the acquired images, line scans were obtained using ImageJ 
software (National Institutes of Health, Bethesda, MD). For 
phalloidin line scans, the half width at half maximum was used to 
indicate thin filament length. Thick filament length was measured 
from myosin line scans (full width at half maximum).
44
Mutation-specific effects on thin filament length in thin filament myopathy 
Sarcomeres in series in a conditional nebulin knockout mouse 
model
For the creation of conditional nebulin knockout mice, see Li and 
coworkers22.  In brief, for conditional nebulin knockout mice, a 
targeting vector was made with loxP sites inserted downstream of 
exon 3 (which contains the start codon for nebulin and corresponds 
to exon 1 of Bang and coworkers11) and in the 5′untranslated 
region of exon 2 upstream of the ATG. Floxed mice were bred to 
a MCK-Cre  strain (#6475; Jackson Laboratory, Bar Harbor, ME) 
that expresses Cre recombinase under control of the muscle 
creatine kinase (MCK) promotor that is expressed in striated 
muscle23.  Genotyping was used to determine the presence of the 
MCK-Cre  transgene (following the protocol provided by Jackson 
Laboratory) and the floxed nebulin allele. Mice homozygous 
for the floxed nebulin allele were bred with mice that were 
hemizygous for MCK-Cre and heterozygous for the floxed allele 
(MCKCre+,  Neb+/flox). Offspring that was hemizygous for MCK-
Cre  and homozygous for the floxed allele (MCKCre+, Neb flox/flox) 
was deficient in nebulin and is referred to as Neb−/−.  We used 
as control offspring that had nebulin wild-type allele and that 
was either MCK-Cre  positive or negative. All animal experiments 
were approved by the University of Arizona Institutional Animal 
Care and Use Committee and followed the US National Institutes 
of Health “Using Animals in Intramural Research” guidelines for 
animal use.
Similar to the methods described above for human muscle fibers, 
permeabilized mouse fibers were activated with exogenous 
calcium at incremental sarcomere lengths to investigate the force–
sarcomere length relation, and confocal microscopy was used to 
determine thin and thick filament length.
In addition, small permeabilized strips were isolated from tendon 
to tendon of mouse soleus muscle and were mounted in a single 
fiber apparatus (ASI 802D, Aurora Scientific) as described 
above in the Permeabilized Muscle Fiber Mechanics section. 




camera and ASI 900B software (Aurora Scientific). Muscle fiber 
length was determined from tendon to tendon. Muscle length was 
divided by the mean sarcomere length to provide the number of 
sarcomeres in series. This number was normalized to tibia length 
(note that tibia length was not different between Neb−/− and Neb+/+ 
mice). 
To determine the sarcomere length at the muscle length that 
generates optimal force, intact left soleus muscles were quickly 
dissected from tendon to tendon and, using silk suture, mounted 
vertically in a tissue bath between a dual-mode lever arm (300C, 
Aurora Scientific) and a fixed hook. Soleus muscles were chosen 
because of their well-defined tendons and their small size, which 
facilitates oxygenation. The muscle was bathed in continuously 
oxygenated (95% O2–5% CO2) mammalian Ringer solution with 
pH=7.40. The temperature of the solution was maintained at 
30°C during the experiment. The muscle was stimulated by 
field stimulation with platinum plate electrodes placed in close 
apposition to the muscle. Optimal muscle length was determined 
by stimulating the muscle maximally at incremental muscle 
lengths, until maximal force was achieved (pulse duration = 200 
microseconds). Then, muscle length was measured from tendon 
to tendon, the muscle was chemically fixed at optimal length, and 
sarcomere length was measured with optical microscopy.
Statistical analyses
Data are presented as mean ± standard error of the mean. For 
statistical analyses, t tests were used. A probability value < 0.05 
was considered statistically significant. 
RESULTS
Muscle fibers were isolated from biopsies of CTRL (n = 8) and 
patients (n = 51) with mutations in NEB  (n = 9), ACTA1  (n = 14), 
TPM3  (n = 12), TPM2 (n = 3), TNNT1  (n = 1), KBTBD13  (n = 10), 
KLHL40  (n = 1), and KLHL41  (n = 1; for patient characteristics, 
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see Supplementary Table 1). From each biopsy, 3 to 9 muscle 
fiber preparations were permeabilized and maximally activated 
with exogenous calcium. Force was measured at incremental 
sarcomere lengths (2.0–3.5μm) to investigate the sarcomere–
length dependency of force.
Maximal Force Generation Is Lower in Muscle Fibers from Thin 
Filament Myopathy Patients
To compare the contractile strength of muscle fibers from 
patients - which typically are atrophic - to those from control 
subjects, the generated forces were normalized to the fibers’ 
cross-sectional area (ie, tension). Hence, maximal active tensions 
of muscle fibers are independent of the diameter of the fibers 
and reflect the intrinsic contractile capacity of the myofilament 
proteins. Lower maximal active tension was observed in all gene 
cohorts, when compared to CTRL muscle fibers (Table). Note that 
the protein product of TPM3  is expressed predominantly in slow-
twitch fibers, and accordingly, slow-twitch fibers from patients 
with mutations in this gene had lower maximal active tension, 
whereas in fast-twitch fibers maximal active tension was similar 
to that of fibers from CTRL. Thus, muscle fibers from patients 
with thin filament myopathy exhibit lower force generation, with 
the most pronounced force loss in patients carrying NEB, ACTA1, 
and KLHL40  mutations.
The Force–Sarcomere Length Relation Is Shifted Downward in 
Muscle Fibers from Patients with Mutations in NEB and ACTA1
Force at incremental sarcomere lengths was fitted using a 2nd 
order polynomial24.  This yielded 3 parameters that describe the 
force–sarcomere length relation: the sarcomere length at which 
maximum force is generated (SLopt),  the sarcomere length at which 
50% of maximum force is generated (SL50), and the sarcomere 
length at which the fit crosses the x-axis, thus no force is generated 
(SLx ;  see Figure 2A). 




individual patients; data from individual subjects are shown in 
Supplementary Table 2. In NEB  patients, a downward shift of 
the descending limb of the force–sarcomere length relation was 
observed, which was accompanied by a significantly shorter 
SLopt (2.41 ± 0.04μm in patients vs 2.61 ± 0.02μm in controls), 
SL50 (3.39 ± 0.05μm in patients vs 3.58 ± 0.03μm in controls), and 












CTRL 8 143±16 2.61±0.03 3.59±0.02 4.03±0.04
NEB 9 *41±11 *2.41±0.08 *3.39±0.07 *3.85±0.08
ACTA1 14 *51±7 2.57±0.02 *3.47±0.02 *3.89±0.03
TPM3 slow-twitch 11 *86±12 2.64±0.04 3.67±0.04 4.14±0.05
TPM3 fast-twitch 7 161±5 2.62±0.06 3.64±0.06 4.10±0.06
TPM2 slow-twitch 2 *56±13 2.68±0.22 3.61±0.18 4.04±0.17
TPM2 fast-twitch 3 150±15 2.56±0.09 3.75±0.07 4.27±0.09
TNNT1 1 50±3 2.60±0.03 3.53±0.12 3.98±0.20
KBTBD13 10 *73±6 2.60±0.04 3.65±0.04 4.13±0.06
KLHL40 1 5.0±2 2.63±0.13 3.66±0.04 4.17±0.07
KLHL41 1 68±4 2.68±0.07 3.60±0.04 4.04±0.05
Table 1. Functional data of thin filament myopathy patients 
and controls
*Significantly different from CTRL (P < 0.05). 
Note that for TNNT1, KLHL40 and KLHL41 one biopsy was evaluated and 
therefore no statistical testing was performed. CTRL: Control, SLopt:  the sarcomere 
length at which maximum force is generated, SL50: the sarcomere length at which 
50% of maximum force is generated, SLx: the sarcomere length at which the fit 
crosses the X-axis. See Supplemental Table 2 for mean values per individual 
subject.
Accordingly, force loss was most prominent at long sarcomere 
lengths, with the force deficit doubling across the operating 
sarcomere length range in human skeletal muscle (~2.9μm [87% 
of CTRL] to 3.6μm [43% of CTRL]25; dashed area and right y-axis 
in Figure 2B. These findings suggest that patients with NEB 
mutations have shorter thin filament lengths.
A novel finding of this study is that mutations in ACTA1 , 
encoding skeletal muscle alpha-actin, the main component of the 
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thin filament, can also cause a significant downward shift of the 
descending limb of the force–sarcomere length relation, with 
significantly shorter SL50 (3.47 ± 0.02μm in patients vs 3.58 ± 0.03μm 
in controls) and SLx (3.89 ± 0.03μm vs 4.02 ± 0.03μm, patients 
vs controls; see Figure 2C). Note that fibers from some NEB 
patients (NEB-1, NEB-4, NEB-5, NEB-8) and some ACTA1 
patients (ACTA1-5, ACTA1-6, ACTA1-9, ACTA1-10) had force–
sarcomere length relations that overlapped with controls (see 
Supplementary Table 2 and Figure 3A). 
For the other thin filament genes that were investigated in this 
study—TPM3 ,  TPM2 ,  TNNT1 ,  KBTBD13 ,  KLHL40 ,  and KLHL41—
no changes in the force–sarcomere length relation were observed 
(see Figure 2D–H and Table). For KLHL40 ,  KLHL41 ,  and 
TNNT1  only 1 biopsy representing each genotype was available 
for contractility experiments; thus, these findings should be 
interpreted with caution. 
Confocal Microscopy Reveals Shorter Thin Filaments in Patients 
with Mutations in NEB and ACTA1
Next, we aimed to confirm that the downward shift of the 
descending limb of the force–sarcomere length relation in patients 
with mutations in NEB  and ACTA1  was caused by shorter thin 
filament length (note that a downward shift of this relation can 
be caused by reduced length of the thin and/or thick filament). 
Therefore, we measured thin and thick filament length by confocal 
microscopy in muscle fibers from NEB  and ACTA1  patients 
exhibiting SL50 values that were in the range of control values 
(NEB-1 and ACTA1-6) and in patients who had values that were 
markedly below this range (NEB-2 and ACTA1-1; see Figure 3A–C). 
Muscle fibers of NEB-2 and ACTA1-1 had shorter thin filament 
lengths than CTRL (0.94 ± 0.12μm in NEB-2 and 0.96 ± 0.06μm 
in ACTA1-1 vs 1.35 ± 0.01μm in CTRL), whereas thick filament 
lengths were comparable to CTRL (1.62 ± 0.02μm in NEB-2 
and 1.56 ± 0.03μm in ACTA1-1 vs 1.61 ± 0.03μm in CTRL). As 
expected, in muscle fibers of NEB-1 and ACTA1-6 normal thin 




(A) The shape of the force–sarcomere length relation is determined by the amount 
of overlap between the thick and thin filament. Force at incremental sarcomere 
lengths is f itted using a 2nd order polynomial. This yields 3 parameters describing 
the force–sarcomere length relation: the sarcomere length at which maximum 
force is generated (SLopt),  the sarcomere length at which 50% of maximum force is 
generated (SL50), and the sarcomere length at which the fit crosses the x-axis (SLx). 
Data shown are from control subjects. The fits represent the mean of individual 
subjects per genotype. (B, C) NEB (n = 9) and ACTA1 (n = 14) muscle fibers 
exhibit a downward shift of the descending limb of the force–sarcomere length 
relation compared to controls. Note that in patients with mutations in NEB (B), 
this results in a doubling of the force deficit (right y-axis) across the in vivo 
sarcomere length range (shaded area). (D–I) Muscle fibers from patients with 
mutations in TPM3 (n = 12), TPM2 (n = 3), TNNT1 (n = 1), KBTBD13 (n = 10), 
KLHL40 (n = 1), and KLHL41 (n = 1) exhibit a preserved force–sarcomere length 
relation. Note that the protein products of TPM3 and TPM2 are predominantly 
expressed in type I f ibers and that these fibers exhibited normal force–sarcomere 
length relations. t tests were per formed between genotype and CTRL; p < 0.05 
was considered statistically significant (indicated by asterisk). 
For each biopsy, 3 to 9 muscle fibers were measured.
Figure 2. The force-sarcomere length relation in muscle fibers 
from thin filament myopathy patients and control subjects
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in ACTA1-6) and thick filament lengths (1.55 ± 0.06μm in NEB-1 
and 1.55 ± 0.02μm in ACTA1-6) were observed. Thus, confocal 
microscopy reveals that thick filament length was not altered in 
any of the samples. This indicates that the downward shift of the 
descending limb of the force sarcomere length relation was caused 
by shorter thin filament length.  
A Mouse Model for Nebulin-Based Thin Filament Myopathy 
Suggests a Compensatory Mechanism for Shorter Thin Filaments 
in Muscle
We addressed whether muscle adds more sarcomeres in series 
to compensate for the sarcomere length-dependent loss of force. 
Adding more sarcomeres in series would blunt the effect of shorter 
thin filament lengths, as at a given muscle fiber length the fibers 
operate at a shorter sarcomere length, a length closer to their 
optimal length. Investigating the number of sarcomeres in series in 
muscle fibers of patients poses considerable technical and ethical 
difficulties. Therefore, we used the recently developed conditional 
nebulin knockout (cNeb−/−) mouse, a model that represents the 
most frequently affected gene in thin filament myopathy, and that 
phenocopies several main features of human disease. (Note that 
muscle fibers from thin filament myopathy patients with NEB 
mutations were also nebulin-deficient; Supplementary Table 3.) 
This model enabled for the first time study of muscle adaptations 
in mature, nebulin-deficient muscle (previous Neb-mouse models 
had a lifespan of maximally 3 weeks). As expected, fibers isolated 
from soleus muscle of adult cNeb−/− mice revealed a downward 
shift of the descending limb of the force–sarcomere length relation 
and confocal microscopy confirmed that the observed downward 
shift was caused by shorter thin filaments (Figure 4A–C). 
Importantly, soleus muscle fibers of cNeb−/− mice contained 
more sarcomeres in series (7,010 ± 176 sarcomeres from tendon 
to tendon) compared to muscle of cNeb+/+ mice (5,903 ± 209 
sarcomeres from tendon to tendon; see Figure 4D). Note that tibia 
length was comparable between cNeb+/+ and cNeb−/− mice. The 




(A–C) Within the NEB and ACTA1 cohorts, fibers of some patients exhibited 
force–sarcomere length relation characteristics that were within the range of 
control (CTRL) values (ie, NEB-1, ACTA1-6), whereas other patients (ie, NEB-2, 
and ACTA1-1) had values that were markedly below this range (normal range for 
sarcomere length at which 50% of maximum force is generated [SL50] is in gray). 
(D–G) Fluorescein isothiocyanate – labeled phalloidin (green) was used to 
measure thin filament length, and antibodies against both slow and fast myosin 
heavy chain isoforms (red) were used to measure thick filament length. Thick 
filament length is normal in muscle fibers from CTRL, NEB, and ACTA1 biopsies, 
whereas thin filaments are shorter in fibers that revealed a downward shift of the 
descending limb of the force–sarcomere length relation (NEB-2 and ACTA1-1; 
n = 4 for CTRL, >5 images per genotype). t tests were performed between genotype 
and CTRL; p < 0.05 was considered statistically significant. (indicated by*).
Figure 3. Confocal microscopy confirms shorter thin filament 
lengths in NEB  and ACTA1  patients
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mice to operate at a shorter sarcomere length, a length closer to 
their optimal sarcomere length. To investigate whether muscle of 
cNeb−/− mice operates at a shorter sarcomere length, whole intact 
soleus muscle was electrically activated and the optimal muscle 
length for force generation was determined. These studies revealed 
that the muscle length at optimal force generation was not different 
between cNeb+/+ and cNeb−/− mice, and that at this muscle length 
the sarcomere length was shorter in cNeb−/− than in cNeb+/+ mice 
(2.51 ± 0.04μm vs 2.80 ± 0.03μm, respectively; see Fig 4E). 
Thus, in cNeb−/− mice, force loss caused by shorter thin filament 
lengths is compensated for by increasing the number of sarcomeres 
in series so that the muscle can operate at shorter sarcomere 
lengths and the amount of overlap between the thin and thick 
filaments is partly restored (summarized in Fig 4F).
DISCUSSION
Ten genes have been implicated in thin filament myopathy. Studies 
focusing on the effects of specific mutations in these genes on 
sarcomere function are largely lacking, mainly because patient 
biopsies have been limited in size and number. However, improved 
insight into genotype–sarcomeric phenotype correlations is 
essential for the development of targeted treatment strategies. 
Therefore, here we investigated the contractile strength of muscle 
fibers in 51 patients, covering 8 of the 10 implicated genes. Lower 
force generation was observed in muscle fibers from patients 
of all genotypes. Shorter than normal thin filament lengths 
were associated with lower force generation in patients with 
thin filament myopathy, but only in those who harbor specific 
mutations in NEB  and ACTA1 .  A conditional Neb  knockout mouse 
model, which recapitulates thin filament myopathy, revealed a 
compensatory mechanism in muscle; force loss due to shorter 





Mutation-Specific Effects on Thin Filament Length
ACTA1  and NEB  are the most frequently mutated genes in 
nemaline myopathy, the most common type of thin filament 
myopathy26. Consequently, shortened thin filaments are likely to 
be a phenotype that contributes to lower force generation in a 
large number of patients with thin filament myopathy. The effect 
of shorter thin filaments on force development is sarcomere- 
and muscle length–dependent, with a more pronounced effect at 
greater lengths. This is illustrated in Figure 2B, where the in vivo 
sarcomere effect at greater lengths. This is illustrated in Figure 2B, 
where the in vivo  sarcomere length range (~2.9–3.6μm25) is 
depicted; in patients with NEB mutations, the force deficit at a 
sarcomere length of 3.6μm doubles compared to the deficit at a 
sarcomere length of 2.9μm. This implies that muscle weakness in 
patients with mutations in NEB  or ACTA1  is more pronounced 
at larger joint angles, where muscle length is long. Whether this 
occurs in thin filament myopathy patients remains to be studied.
As some patients with NEB  and ACTA1  mutations, as well as 
the patients with mutations in TPM3 ,  TPM2 ,  TNNT1 ,  KBTBD13 , 
KLHL40 ,  and KLHL41 ,  displayed significant force deficits without 
a downward shift of the force–sarcomere length relation, other 
mechanisms must be at play in these patients. Previous work on 
animal models and on biopsies from patients with NEB ,  ACTA1 , 
TPM3 ,  and TPM2  showed that qualitative changes in actin–
myosin interactions as well as myofibrillar disarray are important 
contributors to lower force generation6, 12, 27-32.  Similarly, not all 
patients with mutations in NEB  and ACTA1  had shorter thin 
filament lengths; muscle fibers of some patients (NEB-1, NEB-4, 
NEB-5, NEB-8, ACTA1-5, ACTA1-6, ACTA1-9, ACTA1-10) had 
force–sarcomere length relations that overlapped with controls 
(see Supplementary Table 2 and Figure 3A). Thus, within the NEB 
and ACTA1  cohorts, effects on thin filament length are mutation-
specific. Although speculative, one could argue that mutations in 
ACTA1  that reduce the binding strength between actin monomers 
are more likely to impact thin filament length than mutations 
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that occur elsewhere. Similarly, although nebulin is important for 
thin filament length regulation10, 11,  mutations in NEB  that do not 
significantly affect its protein level or binding affinity of capping 
proteins might not disturb the regulation of thin filament length18. 
Investigating mutation-specific effects on thin filament length 
will be an interesting topic for future studies.
In summary, because ACTA1  and NEB  are the most frequently 
mutated genes in thin filament myopathies26,  shortened thin 
filament length is likely to be a phenotype that contributes to 
lower force generation in a large number of patients with thin 
filament myopathy.
Addition of Sarcomeres in Series to Compensate for Shorter Thin 
Filament Length
To date, it has been unknown whether and how muscle responds 
to shorter thin filament lengths. To identify such response, 
we used the recently developed conditional nebulin knockout 
(cNeb−/−) mouse, a model that closely phenocopies human thin 
filament myopathy and, importantly, that made study of muscle 
adaptations in mature Neb-deficient muscle possible for the first 
time. Previous Neb-mouse models had a maximal lifespan of 3 
weeks, and consequently growth retardation and delays in muscle 
development could preclude meaningful explorations of response 
mechanisms. Adult cNeb−/− mice had muscle fibers with shorter 
thin filament lengths, and consequently, in isolated muscle fibers 
the optimal sarcomere length for force production was shorter 
(see Figure 4A–C). However, we observed that cNeb−/− mice 
increased the number of sarcomeres in series, and that as a result 
the optimal muscle length for force generation in intact muscle 
was comparable to cNeb+/+ mice; the addition of sarcomeres in 
series allowed the muscles to operate at a shorter sarcomere 
length (see Figure 4D–F), a length closer to their optimal 
sarcomere length. Adapting the number of sarcomeres in series to 
compensate for the changes in thin filament length suggests the 




Figure 4. A mouse model for nemaline myopathy compensates 
for shorter thin filaments by adding more sarcomeres in serie
(A) Soleus muscle fibers from a mouse model that phenocopies human nemaline 
myopathy (conditional nebulin knockout, cNeb-/-) revealed a downward shift of 
the descending limb of the force–sarcomere length relation compared to muscle 
fibers from cNeb+/+ mice (n = 4 mice/group). (B, C) Confocal microscopy revealed 
shorter thin filaments in cNeb-/- mice. (D) cNeb-/- mice compensated for the force 
deficit caused by shorter thin filaments by increasing the number of sarcomeres in 
series (n = 6 mice/group). (E) At optimal length for force generation, intact soleus 
muscle of cNeb-/- mice operated at a shorter sarcomere length (SL) than cNeb+/+ mice 
(n = 20 mice/group). (F) The addition of sarcomeres in series increases the 
amount of overlap between the thin and thick filaments and enables the fibers 
with shorter thin filaments to operate at a length closer to their optimal length. 
t tests were performed between cNeb+/+ and cNeb-/- mice, p < 0.05 was considered 
statistically significant (indicated by asterisk). SLopt = SL at which maximum 
force is generated; SL50 = SL at which 50% of maximum force is generated; SLx = 
SL at which the fit crosses the x-axis. (indicated by*) 
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mechanisms that underlie this remain to be revealed, but might 
include proteins that sense suboptimal filament overlap, and in 
response produce more sarcomeric proteins. Previous work on 
animal models suggested that IGF-1, Akt, and cytosolic calcium 
mediate the addition of sarcomeres in series33-35.  Whether these 
mediators are players in sensing optimal filament overlap and 
are involved in the regulation of sarcomeric protein expression 
remains to be elucidated. Future studies should address whether 
this compensatory mechanism is also present in human diseased 
muscle and whether active stretching of muscle stimulates the 
addition of sarcomeres in series, as observed in rodents36.
Study limitations
The mutations in some of the genes that are implicated in thin 
filament myopathy are rare, which precludes the inclusion of large 
numbers of patients. We were able to study only 1 patient with a 
mutation in KLHL40 ,  1 with a mutation in KLHL41 ,  and 1 with a 
mutation in TNNT1 ,  and the force–sarcomere length relations in 
muscle fibers of these 3 patients were comparable to that in fibers of 
control subjects. Caution is warranted when drawing conclusions 
from this small sample size, and future studies on more patients 
with mutations in these genes should test whether thin filament 
length is unaffected. Second, muscle fibers in biopsies of several 
patients were very small,  which precluded studies on individual 
fibers and forced us to use multifiber preparations. Previous 
work from our group revealed that the maximal active tension 
determined in single fibers is comparable to that determined in 
multifiber preparations37.  Thus, it is unlikely that our results are 
affected by using both single and multifiber preparations.
Summary
We investigated a large cohort of patients covering the majority 
of genes that are implicated in thin filament myopathy. Lower 
force generation at the sarcomere level was observed in muscle 
fibers from patients of all genotypes that were studied. Shorter 




force generation in patients with thin filament myopathy, but 
only in those who harbor specific mutations in NEB  or ACTA1 . 
Findings in a conditional Neb  knockout mouse model suggest that 
in thin filament myopathy patients adding more sarcomeres in 
series might be a novel direction in counteracting force loss.
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SUPPLEMENTAL TABLES





(year) Mutation Patient ID Disease
Clinical 
severity References
CTRL-1 46 N/A N/A N/A N/A Yuen et al., 2015
CTRL-2 31 N/A N/A N/A N/A Yuen et al., 2015
CTRL-3 54 N/A N/A N/A N/A Yuen et al., 2015
CTRL-4 21 N/A N/A N/A N/A Yuen et al., 2015
CTRL-5 39 N/A N/A N/A N/A Yuen et al., 2015
CTRL-6 11 N/A N/A N/A N/A Yuen et al., 2015
CTRL-7 35 N/A N/A N/A N/A Yuen et al., 2015





(year) Mutation Patient ID Disease
Clinical 
severity References
NEB-1 12 p.[Tyr2655Cys]; [Trp3876*] BOS12-3|T472 NM Typical Lehtokari et al., 2014
NEB-2 0.1 p.[Tyr2549*]; [Arg3016*] BOS227-1|159 NM Severe Lehtokari et al., 2014
NEB-3 5 p.[Glu666Val]; [?] BOS1027-1| T1139 NM Intermediate Unpublished
NEB-4 0.5 p.[Arg8245fs]; [?] 11700 NM Intermediate Malfatti et al., 2014
NEB-5 0.8 p.[Thr8085fs]; [?] NM Intermediate Malfatti et al., 2014
NEB-6 6 p.[Arg1747_ 8536 NM Typical Malfatti et al., 2014
NEB-7 6 p.[Ser8193Ser]; [Gln6226*] 12188 NM Typical
Lehtokari et al.,2014, 
Malfatti et al., 2014





N/A NM Severe Malfatti et al., 2014
1NEB  numbering relative to NP_001258137.1 
? Note that for NEB-3, NEB-4, NEB-5 and NEB-8 only one pathogenic 







Age (year) Mutation Patient ID Disease Clinical severity References
ACTA1-1 0.6 p. Gly57Arg BOS922-1 | T866 NM Typical Unpublished
ACTA1-2 0.8 p. Thr79Ala BOS95-1 | T77 NM Typical Laing et al., 2009
ACTA1-3 2.8 p. Glu85Lys BOS349-1 | T256 NM Typical Laing et al., 2009
ACTA1-4 0.2 p. Arg258His BOS927-1 | T865 NM Typical Unpublished
ACTA1-5 3 p. Ala274Glu N/A NM Typical Laing et al., 2009
ACTA1-6 60 p. Ala206Thr N/A NM Mild Laing et al., 2009
ACTA1-7 5 p. Gly270Cys N/A NM Childhood onset Ilkovski et al., 2001
ACTA1-8 0.1 p. Asp294Val N/A Intermediate Laing et al., 2004
ACTA1-9 65 p. Val165Met N/A NM Mild Hutchinson et al., 2006
ACTA1-10 17 p. Asn117Ser N/A NM Childhood onset Ilkovski et al., 2001
ACTA1-11 0.1 p. Leu223Pro N/A Severe Laing et al., 2004
ACTA1-12 0.1 p. Asp186His N/A NM Severe Unpublished
ACTA1-13 0.8 p. Pro334Ser N/A Severe Laing et al., 2004
ACTA1-14 36 p. Arg185Cys N/A NM Intermediate Nowak et al., 1999
2T number indicates biopsy number according to Boston Children’s Hospital registry.
Note that the clinical scale is according to Lehtokari et al., 2015. ‘Typical’ NM is classified as: Onset 
in infancy: typical distribution of muscle weakness (weakness most pronounced in facial, bulbar, and 
respiratory muscles, neck flexors, and limb-girdle muscles; initially proximal, later also distal limb 
involvement); motor milestones delayed but reached; course slowly progressive or non-progressive.
3ACTA1 numbering relative to NP_001091.1
2
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ID Disease Clinical severity References
TPM3-1 10 p. Arg168Gly N/A CFTD Mild Yuen et al., 2015, Clarke et al., 2008
TPM3-2 3 p. Leu100Met N/A CFTD Mild Yuen et al., 2015, Clarke et al., 2008
TPM3-3 40 p. Arg168H N/A CFTD Mild Yuen et al., 2015
TPM3-4 30 p. Leu100Met N/A CFTD Mild Yuen et al., 2015, Clarke et al., 2008
TPM3-5 17 p. Arg168Cys N/A Cap Mild Yuen et al., 2015, Waddell et al., 2010
TPM3-6 1.3 p. Lys169Glu N/A CFTD Mild Yuen et al., 2015, Clarke et al., 2008
TPM3-7 1.7 p. Arg245Gly N/A CFTD Mild to moderate
Yuen et al., 2015, 
Clarke et al., 2008
TPM3-8 56 p. Arg168His N/A CFTD Mild Yuen et al., 2015, Clarke et al., 2008
TPM3-9 36 p. Leu100Met N/A CFTD Mild Yuen et al., 2015, Clarke et al., 2008
TPM3-10 19 p. Arg168Cys N/A CFTD Mild to moderate
Yuen et al., 2015 
Clarke et al., 2008,
Waddell et al., 2010
TPM3-11 0.1 p. Glu218del N/A N/A Severe Donkervoort et al., 2015
TPM3-12 1.4 p. Glu224del N/A N/A Severe Donkervoort et al., 2015










TPM2-1 10 p. Glu139del N/A Cap Mild Clarke et al., 2009
TPM2-2 7 p. Lys7del N/A NM Mild Mokbel et al., 2013
TPM2-3 41 p. Lys7del N/A NM Mild Mokbel et al., 2013
5TPM2 numbering relative to NP_003280.2
Troponin 









TNNT1-1 0.6 p. Leu203stop N/A NM Severe Abdulhaq et al., 2015
6TNNT1 numbering relative to NP_003274.3
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KBTBD13-1 44 p. Arg408Cys N/A NM Mild Sambuughin et al., 2010
KBTBD13-2 45 p. Arg408Cys N/A NM Mild Sambuughin et al., 2010
KBTBD13-3 42 p. Arg408Cys N/A NM Mild Unpublished
KBTBD13-4 41 p. Lys390Asn N/A NM Mild Sambuughin et al., 2010
KBTBD13-5 16 p. Arg408Cys N/A NM Mild Unpublished
KBTBD13-6 46 p. Arg408Cys N/A NM Mild Gommans et al., 2003
KBTBD13-7 55 p. Ile369Met N/A NM Mild Unpublished
KBTBD13-8 46 p. Arg408Cys N/A NM Mild Sambuughin et al., 2010
KBTBD13-9 62 p. Arg408Cys N/A NM Mild Sambuughin et al., 2010
KBTBD13-10 34 p. Arg408Cys N/A NM Mild Sambuughin et al., 2010






(year) Mutation Patient ID Disease
Clinical  
severity References
KLHL40-1 0.1 p. [Asp34His]; [Leu86Pro]
BOS74-4| 
T545 NM Severe Ravenscroft et al., 2013












KLHL41-1 4.5 p. [Ser153_Ala154insLeu] BOS832-1| T823 NM Mild Gupta et al., 2013
9KLHL41 numbering relative to NP_006054.2
2
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CTRL-1 151±20 2.69±0.04 3.49±0.02 3.85±0.03
CTRL-2 120±13 2.56±0.05 3.62±0.06 4.09±0.07
CTRL-3 125±12 2.61±0.05 3.66±0.05 4.13±0.1
CTRL-4 238±25 2.62±0.09 3.57±0.05 3.99±0.06
CTRL-5 154±11 2.65±0.07 3.63±0.05 4.06±0.04
CTRL-6 109±25 2.44±0.05 3.66±0.04 4.18±0.08
CTRL-7 143±16 2.71±0.06 3.55±0.09 3.93±0.12
CTRL-8 82±16 2.60±0.06 3.52±0.09 3.94±0.12












NEB-1 74±25 2.73±0.06 3.63±0.05 4.05±0.06
NEB-2 18±5 2.37±0.1 3.29±0.08 3.69±0.09
NEB-3 9±2 2.38±0.01 3.12±0.1 3.46±0.13
NEB-4 15±1 2.39±0.05 3.55±0.03 4.10±0.06
NEB-5 51±18 2.75±0.21 3.56±0.19 3.96±0.22
NEB-6 60±6 2.03±0.12 3.05±0.04 3.51±0.11
NEB-7 108±28 2.32±0.15 3.34±0.05 3.79±0.1
NEB-8 30±4 2.58±0.04 3.54±0.03 4.02±0.03
NEB-9 10±2 2.16±0.52 3.44±0.13 4.05±0.4














ACTA1-1 43±10 2.43±0.1 3.34±0.1 3.77±0.13
ACTA1-2 28±7 2.52±0.08 3.49±0.06 3.93±0.05
ACTA1-3 92±15 2.48±0.13 3.45±0.06 3.89±0.06
ACTA1-4 31±7 2.51±0.11 3.45±0.08 3.90±0.17
ACTA1-5 48±9 2.63±0.07 3.53±0.04 3.92±0.07
ACTA1-6 86±22 2.57±0.05 3.53±0.06 3.96±0.09
ACTA1-7 30±5 2.60±0.04 3.34±0.09 3.67±0.12
ACTA1-8 33±6 2.68±0.08 3.41±0.1 3.75±0.12
ACTA1-9 71±9 2.57±0.09 3.53±0.08 3.96±0.11
ACTA1-10 76±14 2.45±0.06 3.49±0.1 3.97±0.15
ACTA1-11 52±11 2.66±0.03 3.47±0.04 3.83±0.03
ACTA1-12 5±1 2.62±0.04 3.40±0.12 3.78±0.12
ACTA1-13 87±15 2.47±0.05 3.47±0.04 3.92±0.03
ACTA1-14 25±15 2.72±0.1 3.71±0.09 4.17±0.13















TNNT1-1 50±3 2.60±0.03 3.53±0.12 3.98±0.20













KBTBD13-1 93±6 2.74±0.14 3.50±0.07 3.84±0.07
KBTBD13-2 64 2.37 3.63 4.24
KBTBD13-3 51±6 2.58±0.05 3.51±0.07 3.91±0.07
KBTBD13-4 87±5 2.52±0.16 3.52±0.1 3.94±0.01
KBTBD13-5 74±7 2.68±0.08 3.67±0.05 4.12±0.06
KBTBD13-6 68±13 2.63±0.06 3.85±0.07 4.37±0.08
KBTBD13-7 45±9 2.73±0.10 3.78±0.07 4.27±0.10
KBTBD13-8 71±14 2.50±0.13 3.73±0.05 4.28±0.10
KBTBD13-9 71±9 2.52±0.05 3.66±0.05 4.16±0.07
KBTBD13-10 103±13 2.72±0.07 3.68±0.07 4.15±0.07











































Slow Fast Slow Fast Slow Fast Slow Fast
TPM3-1 71±7 2.70±0.14 3.72±0.07 4.18±0.07
TPM3-2 144±23 156±22 2.69±0.03 2.76±0.04 3.78±0.02 3.77±0.12 4.23±0.04 4.21±0.18
TPM3-3 112 165±28 2.78 2.74±0.13 3.79 3.75±0.08 4.26 4.21±0.12
TPM3-4 95±8 2.61±0.04 3.69±0.1 4.24±0.12
TPM3-5 66±8 2.50±0.12 3.53±0.07 4.04±0.12
TPM3-6 22±1 2.71 3.51 3.87
TPM3-7 74±19 176±20 2.61±0.03 3.69±0.14 4.16±0.18
TPM3-8 122±24 164±21 2.71±0.05 2.47±0.22 3.64±0.09 3.51±0.14 4.05±0.09 3.95±0.11
TPM3-9 66±10 2.44±0.1 3.66±0.11 4.21±0.13
TPM3-10 144±12 2.53±0.04 3.48±0.04
TPM3-11 10±1 2.28±0.15 3.51±0.04 4.12±0.09
TPM3-12 68±8 2.54±0.06 3.47±0.05 3.90±0.05
Mean *86±12 161±5 2.64±0.04 2.62±0.06 3.67±0.04 3.64±0.06 4.14±0.05 4.10±0.06
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Slow Fast Slow Fast Slow Fast Slow Fast
TPM2-1 130±6 2.60±0.07 3.75±0.07 4.27±0.09
TPM2-2 43 140 2.89 2.68 3.79 4.21
TPM2-3 68±9 180±19 2.46±0.06 2.39±0.09 3.43±0.19 3.87±0.27
Mean *56±13 150±15 2.68±0.22 2.56±0.09 3.61±0.18 3.75±0.07 4.04±0.17 4.27±0.09
* Significantly different from CTRL (P < 0.05). Note that for TNNT1, KLHL40 and KLHL41 one biopsy 
was evaluated and therefore no statistical testing was performed. SLopt: the sarcomere length at which 
maximum force is generated, SL50: the sarcomere length at which 50% of maximum force is generated, 
Table 3. Nebulin levels by Western blot analysis
Genotype Number of biopsies Nebulin levels by Western blot / Myosin heavy chain levels by PonceauS staining
CTRL 5 2.67±0.3
NEB 7 *1.55±0.3
*Significantly different from CTRL (P < 0.05)


